Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
J Gynecol Oncol
; 35(2): e66, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38330382
ABSTRACT
In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Neoplasias do Colo do Útero
/
Neoplasias do Endométrio
/
Neoplasias dos Genitais Femininos
Limite:
Female
/
Humans
Idioma:
En
Revista:
J Gynecol Oncol
/
J. gynecol. oncol. (Online)
/
Journal of gynecologic oncology (Online)
Ano de publicação:
2024
Tipo de documento:
Article